The current price of BNTC is $9.35 — it has increased by 8.22% since the previous close. Data as of Nov 6, 2026.
BNTC is up 6.36% over the past week, up 4.00% over the past month and down 22.00% over the past year. The price is below its 200-day moving average of $11.48.
Analysts' average 12-month price target for BNTC is $18.67, which implies 99.68% upside from the current price. Individual estimates range from $14.00 to $25.00.
Of the 8 analysts covering Benitec Biopharma Inc., 2 rate it a strong buy and 6 rate it a buy. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Benitec Biopharma Inc. has a market capitalization of $326.21M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Benitec Biopharma Inc. posted a loss of $0.26 per share against an estimate of -$0.2643, beating expectations by 1.62%. Upcoming reports are listed in the earnings calendar.
Benitec Biopharma Inc. has not paid any dividends over the past year.
In the latest trading session BNTC moved between $8.79 and $9.41, a range of 6.63% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Benitec Biopharma Inc. shows a neutral rating today and a sell rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Benitec Biopharma Inc. is sell. Technical ratings are indicators, not investment advice.
Over the past 52 weeks BNTC has traded between $7.89 and $14.39. The current price is 35.02% below its 52-week high.
Figures as of Nov 6, 2026. This information is provided for general purposes only and is not investment advice.